Glutathione vs Orforglipron
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & LongevityImmune Support
GlutathioneGLP-1 / Weight Loss Agonists
Orforglipron- Summary
- Glutathione is the body's master endogenous antioxidant tripeptide, composed of glutamate, cysteine, and glycine. It neutralizes reactive oxygen species, supports detoxification in the liver, recycles other antioxidants (vitamins C and E), and plays a central role in immune function, DNA repair, and cellular redox balance.
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Half-Life
- Minutes to hours depending on route; IV half-life approximately 10-30 minutes
- ~12 hours (once-daily oral dosing)
- Admin Route
- Oral (liposomal preferred), Sublingual, Intravenous, Nebulized/inhaled, Topical
- Oral
- Research
- —
- —
- Typical Dose
- 250-1000 mg per day
- 12 mg → 24 mg → 36 mg → 45 mg
- Frequency
- Once or twice daily
- Once daily
- Key Benefits
- Primary endogenous antioxidant and free radical scavenger
- Supports hepatic detoxification of xenobiotics and heavy metals
- Recycles vitamins C and E to maintain antioxidant network
- Modulates immune function and T-cell activity
- Skin brightening via inhibition of tyrosinase (IV/topical routes)
- Neuroprotective in oxidative stress-related conditions
- Mitochondrial protection and energy metabolism support
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Side Effects
- Oral bioavailability is limited (largely hydrolyzed in gut); liposomal or sublingual forms preferred
- IV administration: rare allergic reactions, vein irritation
- High-dose supplementation may cause zinc depletion over time
- Inhaled glutathione may trigger bronchoconstriction in asthmatics
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Stacks With
- —
- —